Background: Biotin has gained commercial popularity for its claimed benefits on healthy hair and nail growth. Despite its reputation, there is limited research to support the utility of biotin in healthy individuals. Objective: To systematically review the literature on biotin efficacy in hair and nail growth. Methods: We conducted a PubMed search of all case reports and randomized clinical trials (RCTs) using the following terms: (biotin and hair); (biotin and supplementation and hair); (biotin supplementation); (biotin and alopecia); (biotin and nails); (biotin and dermatology), and (biotin recommendations). Results: We found 18 reported cases of biotin use for hair and nail changes. In all cases, patients receiving biotin supplementation had an underlying pathology for poor hair or nail growth. All cases showed evidence of clinical improvement after receiving biotin. Conclusions: Though its use as a hair and nail growth supplement is prevalent, research demonstrating the efficacy of biotin is limited. In cases of acquired and inherited causes of biotin deficiency as well as pathologies, such as brittle nail syndrome or uncombable hair, biotin supplementation may be of benefit. However, we propose these cases are uncommon and that there is lack of sufficient evidence for supplementation in healthy individuals.

Biotin (also known as vitamin B7 or vitamin H) is a water-soluble vitamin that serves as an essential cofactor for carboxylase enzymes in multiple metabolic pathways. Due to its relatively low cost and abundance of availability in cosmetic products, biotin has become the new trend for consumers wishing to have longer, healthier hair and nails. Current recommendations for biotin by the Institute of Medicine state that the daily adequate intake (AI) for adults is 30 μg/day [1]. Most healthy individuals meet these requirements through a well-balanced diet, though many still take up to 500-1,000 μg of biotin supplementation daily. Although no major toxicities of excess biotin have been reported, data on the actual benefit of biotin's effect on hair and nail growth is limited. Moreover, outside the setting of pregnancy, malnutrition, medication effects, and biotinidase deficiency in children, reports of low biotin levels have rarely been cited. Therefore, we propose that true biotin deficiency is uncommon and that there is lack of sufficient evidence for supplementation for hair and nail growth in individuals who do not present with low levels of biotin.

We conducted a PubMed search of all case reports and randomized clinical trials (RCTs) published using the following terms: (biotin and hair); (biotin and supplementation and hair); (biotin supplementation); (biotin and alopecia); (biotin and nails); (biotin and dermatology), and (biotin recommendations). We identified additional sources through references contained in the original articles. We limited our search to studies discussing human subjects only. Through this search, we found 18 reported cases of biotin use for hair and nail changes (Table 1).

Table 1

Reported cases of patients categorized by age, dose of biotin, symptoms, and length of treatment until clinical improvement

Reported cases of patients categorized by age, dose of biotin, symptoms, and length of treatment until clinical improvement
Reported cases of patients categorized by age, dose of biotin, symptoms, and length of treatment until clinical improvement

Of the reported cases in the literature, all patients receiving biotin supplementation had some underlying pathology for either poor hair or nail growth. Moreover, all cases showed evidence of clinical improvement after receiving biotin. Time to improvement as well as dosage administered varied for each case. Ten of the 18 cases were reports of patients with inherited enzyme deficiency in either biotinidase or holocarboxylase synthetase. Of these 10, 8 cases reported alopecia that subsequently resolved after varying months of biotin supplementation. Additionally, there were 3 reported cases of uncombable hair syndrome that all showed improvement in hair quality after a few months of treatment. Fujimoto et al. [4] reported a case of biotin deficiency secondary to diet in an infant who was consuming a special amino acid formula. This patient had low serum and urine levels of biotin as well as perioral dermatitis and alopecia. Hair regrowth in this patient occurred after 2 months of biotin supplementation. Only 1 study conducted by Castro-Gago et al. [14] showed decreased levels of both biotin and biotinidase secondary to medication usage (valproic acid) that improved after 3 months of supplementation with biotin. Finally, 3 cases of brittle nail syndrome treated with biotin were found in the literature and each case showed improvement of nail strength as well as growth on either 2,500 or 3,000 μg of biotin/day.

Biotin is a required cofactor for carboxylase enzymes that become activated once they are joined together by holocarboxylase synthase [18]. These enzyme complexes play an important role in multiple metabolic processes including gluconeogenesis, fatty acid synthesis, and amino acid catabolism [19]. Biotin's function in protein synthesis and more specifically, in keratin production, explains its contribution to healthy nail and hair growth. Biotin is readily found in many foods and is also produced by normal gut flora. Foods found to have high amounts of biotin include nuts, legumes, whole grains, unpolished rice, and egg yolk [20]. Recommended daily allowances of biotin have not been established due to a lack of sufficient evidence [21]. However, AI levels have been recommended by the Food and Nutrition Board of the Institute of Medicine (Table 2). It has been estimated that in Western populations, typical dietary intake of biotin is between 35 and 70 μg/day [22]. Though several animal models [23,24,25] demonstrating the effects of induced biotin deficiency can be found in the literature, there are currently no studies that show biotin deficiencies in healthy human individuals with balanced diets.

Table 2

Established AI levels of biotin per the Food and Nutrition Board of the Institute of Medicine [1]

Established AI levels of biotin per the Food and Nutrition Board of the Institute of Medicine [1]
Established AI levels of biotin per the Food and Nutrition Board of the Institute of Medicine [1]

Biotin deficiency can be either acquired or congenital. Though an acquired biotin deficiency is possible, it is still rare. A commonly documented cause of acquired biotin deficiency is secondary to increased raw egg consumption. The protein avidin, found in raw egg whites, can be denatured through cooking, but when uncooked, this protein binds to biotin tightly preventing it from being used as an essential cofactor [26]. Patients taking anticonvulsant medications, such as valproic acid, can also become deficient, and therefore, are prophylactically administered biotin [21]. Additional causes of acquired biotin deficiency include states of alcoholism or pregnancy, other medications, such as isotretinoin [27], impaired intestinal absorption, or prolonged use of antibiotics interrupting normal gut flora [18,23,24]. Congenital or genetic biotin deficiency is due to an autosomal recessive trait leading to a lack of either holocarboxylase synthase or biotinidase. When it occurs within the first 6 weeks of life, this deficiency is defined as the neonatal type. In this type of biotin deficiency, the enzyme holocarboxylase synthetase is absent and patients typically have severe, life-threatening conditions [18,28,29]. Beyond 3 months of life, the infantile form predominates and is defined by a biotinidase deficiency which is involved in the absorption of free biotin following carboxylase degradation [18,28,30]. Whether acquired or congenital, typical symptoms of biotin deficiency include alopecia, eczematous skin rashes, seborrheic dermatitis, conjunctivitis, and multiple neurological symptoms, such as depression, lethargy, hypotonia, and seizures [3,20]. While the neurological symptoms occur at more severe levels of biotin deficiency, the dermatological manifestations often appear first and are therefore an important indicator [31]. The normal biotin plasma concentration ranges from 400 to 1,200 ng/L [22]. Deficiency is technically considered to be a level of less than 200 ng/L. However, plasma biotin levels can fluctuate daily and thus are not considered to be a sensitive marker [22]. A more validated measure of biotin deficiency is an increased urinary excretion of the metabolite, 3-hydroxyisovaleric acid (normal level: 195 μmol/24 h) [22].

In our search, we found 18 reports in the literature that showed improvement of hair and nail growth on supplementation in patients with established biotin deficiency. For patients with inherited enzyme deficiency, larger doses of biotin supplementation are recommended (from 10,000 to 30,000 μg/day). Those with brittle nail syndrome and other underlying hair pathologies, such as uncombable hair syndrome, require much lower doses of biotin supplementation ranging from 300 to 3,000 μg/day. Despite these data, there have been no randomized, controlled trials to prove the efficacy of supplementation with biotin in normal, healthy individuals. Moreover, only 1 case in the literature has measured the levels of biotin in normal individuals that had complaints of hair loss. In this study of 541 women (age range between 9 and 92 years), 38% had low biotin levels [20]. However, of those women, 11% were later found through patient history (use of antibiotics, antiepileptics, isotretinoin, or GI disease) to have a reason for the underlying deficiency and 35% had co-existing seborrheic dermatitis, suggesting a multifactorial cause for hair loss. Additionally, in vitro studies have shown that proliferation and differentiation of normal, nonpathologic follicular keratinocytes are not influenced by biotin [27].

Despite its popularity in the media and amongst consumers, biotin has no proven efficacy in hair and nail growth of healthy individuals. Only 1 study has shown decreased levels of biotin in healthy individuals, though this data was confounded by multiple factors, including patient history. Therefore, in the absence of additional studies, we have found no evidence to suggest benefit from biotin supplementation outside of known deficiencies secondary to congenital or acquired causes.

The authors declare no conflicts of interest pertaining to the current publications.

Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and Its Panel on Folate, Other B Vitamins, and Choline. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, National Academies Press (US), 1998.
Dakshinamurti K, Triggs-Raine B: Biotin and Multiple Carboxylase Deficiency. Clinical Studies in Medical Biochemistry. Oxford University Press, 1997.
Rajendiran A, Sampath S: Biotinidase deficiency - clinching the diagnosis rapidly can make all the difference! BMJ Case Reports 2011;2011.pii:bcr0720114494. doi 10.1136/bcr.07.2011.4494.
Fujimoto W, Inaoki M, Fukui T, et al: Biotin deficiency in an infant fed with amino acid formula. J Dermatol 2005;32:256-261.
Colamaria V, Burlina AB, Gaburro D, Pajno-Ferrara F, Saudubray JM, Merino RG, Bemardina BD: Biotin-responsive infantile encephalopathy: EEG-polygraphic study of a case. Epilepsia 1989;30:573-578.
Coulter DL, Beals TF, Allen RJ: Neurotrichosis: hair-shaft abnormalities associated with neurological diseases. Dev Med Child Neurol 1982;24:634-644.
Boccaletti V, Zendri E, Giordano G, Gnetti L, De Panfilis G: Familial uncombable hair syndrome: ultrastructural hair study and response to biotin. Pediatric Dermatol 2007;24:E14-E16.
Shelley WB, Shelley ED: Uncombable hair syndrome: observations on response to biotin and occurrence in siblings with ectodermal dysplasia. J Am Acad Dermatol 1985;13:97-102.
Mukhopadhyay D, Das MK, Dhar S, Mukhopadhyay M: Multiple carboxylase deficiency (late onset) due to deficiency of biotinidase. Indian J Dermatol 2014;59:502-504.
Komur M, Okuyaz C, Ezgu F, Atici A: A girl with spastic tetraparesis associated with biotinidase deficiency. Eur J Pediatr Neurol 2011;15:551-553.
Gannavarapu S, Prasad C, DiRaimo J, et al: Biotinidase deficiency: spectrum of molecular, enzymatic and clinical information from newborn screening Ontario, Canada (2007-2014). Mol Genet Metab 2015;116:146-151.
Rahman S, Standing S, Dalton RN, Pike MG: Late presentation of biotinidase deficiency with acute visual loss and gait disturbance. Dev Med Child Neurol 1997;39:830-831.
Roth KS, Yang W, Foremann JW, Rothman R, Segal S: Holocarboxylase synthetase deficiency: a biotin-responsive organic acidemia. J Pediatr 1980;96:845-849.
Castro-Gago M, Perez-Gay L, Gomez-Lado C, et al: The influence of valproic acid and carbamazepine treatment on serum biotin and zinc levels and on biotinidase activity. J Child Neurol 2011;26:1522-1524.
Hochman LG, Scher RK, Meyerson MS: Brittle nails: response to daily biotin supplementation. Cutis 1993;51:303-305.
Colombo VE, Gerber F, Bronhofer M, Floersheim GL: Treatment of brittle fingernails and onychoschizia with biotin: scanning electron microscopy. J Am Acad Dermatol 1990;23(6 Pt 1):1127-1132.
Floersheim GL: Treatment of brittle fingernails with biotin. Z Hautkr 1989;15:64:41-48.
Goldberg LJ, Lenzy Y: Nutrition and hair. Clin Dermatol 2010;28:412-419.
Glew RH, Stephen PP: Clinical studies in medical biochemistry. New York, Oxford University Press, 1987.
Trüeb RM: Serum biotin levels in women complaining of hair loss. Int J Trichology 2016;8:73-77.
Higdon J, Drake VJ: An evidence-based approach to vitamins and minerals. Google books. New York, Thieme, 2012. (accessed March 16, 2010).
Zempleni J, Mock DM: Biotin biochemistry and human requirements. J Nutr Biochem 1999;10:128-138.
Finner AM: Nutrition and hair deficiencies and supplements. Dermatol Clin 2013;31:167-172.
Zempleni J, Hassan YI, Wijeratne SSK: Biotin and biotinidase deficiency. Expert Rev Endocrinol Metab 2008;3:715-724.
Rushton DH: Nutritional factors and hair loss. Clin Exp Dermatol 2002;27:396-404.
Mock DM: Skin manifestations of biotin deficiency. Semin Dermatol 1991;10:296-302.
Schulpis KH, Georgala S, Papakonstantinou ED, et al: The effect of isotretinoin on biotinidase activity. Skin Pharmacol Appl Skin Physiol 1999;12:28-33.
Miller SJ: Nutritional deficiency and the skin. J Am Acad Dermatol 1989;21:1-30.
Nyhan WL: Inborn errors of biotin metabolism. Arch Dermatol 1987;123:1696a-1698a.
Venkataraman V, Balaji P, Panigrahi D, et al: Biotinidase deficiency in childhood. Neurol India 2013;61:411-413.
Limat A, Suormala T, Hunziker T, Waelti ER, Braathen LR, Baumgartner R: Proliferation and differentiation of cultured human follicular keratinocytes are not influenced by biotin. Arch Dermatol Res 1996;288:31-38.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.